Work

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors

Year: 2014

Type: article

Study design: Clinical Trial

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-13-2403

Authors: Kyriakos P. Papadopoulos, Josep Tabernero, Ben Markman, Amita Patnaik, Anthony W. Tolcher, José Baselga, Weiliang Shi, Coumaran Egile, Rodrigo Ruiz-Soto, A. Douglas Laird, Dale Miles, Patricia M. LoRusso

Institutions: Universitat Autònoma de Barcelona, Memorial Sloan Kettering Cancer Center, Exelixis (United States), Wayne State University, Sanofi (France), The Barbara Ann Karmanos Cancer Institute, South Texas Accelerated Research Therapeutics, Memorial Hospital, Monash University, Monash Institute of Medical Research

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2126390772

FWCI: 5.84

Cites: 25

Cited by: 95

Related to: 10